20-F/A: ImmunoPrecise Antibodies Ltd. Files Amended Annual Report to Correct Typographical Error

ImmunoPrecise Antibodies Ltd. has filed an amendment to its annual report on Form 20-F to correct a typographical error regarding the fiscal period.

Summary

• ImmunoPrecise Antibodies Ltd. filed an amendment to its annual report on Form 20-F, designated as Form 20-F/A, to correct a typographical error.
• The original report was filed on July 29, 2024, and this amendment, filed on December 10, 2024, addresses an error in the fiscal period presented under Item 15.
• The amendment does not reflect any events occurring after the original filing date and does not modify or update any other disclosures.
• The company's management, including the CEO and CFO, have certified that the disclosure controls and procedures were effective as of April 30, 2024.
• Management also concluded that the company's internal control over financial reporting was appropriately designed and effective as of April 30, 2024.
• There were no changes in the company's internal control over financial reporting during the year ended April 30, 2024 that materially affected or are reasonably likely to materially affect the internal control over financial reporting.
• The company is an emerging growth company and is exempt from the requirement to include an auditor attestation report on internal control over financial reporting.

Sentiment

Score: 7

Explanation: The document is a routine amendment to correct a minor error, which is a neutral event. The company's statements about the effectiveness of its controls are positive, but the inherent limitations of control systems are also acknowledged. Overall, the sentiment is slightly positive.

Positives

• The company has corrected a typographical error in its annual report, demonstrating attention to detail.
• Management has certified the effectiveness of both disclosure controls and internal control over financial reporting.
• There were no material changes to internal controls during the fiscal year, indicating stability in financial reporting processes.

Risks

• While the company states that internal controls are effective, there are inherent limitations in all control systems, and they cannot provide absolute assurance against all misstatements or fraud.
• The company's status as an emerging growth company means it is exempt from certain reporting requirements, which could be seen as a risk by some investors.

Future Outlook

The company will continue to monitor the effectiveness of its internal control over financial reporting and disclosure controls and procedures and may make modifications from time to time as considered necessary.

Management Comments

• Management of the Company, including the CEO and CFO, believe that disclosure controls and procedures and internal control over financial reporting, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met.
• Management concluded that our internal control over financial reporting were appropriately designed and effective as at April 30, 2024 and provided a reasonable assurance of the reliability of our financial reporting and preparation of financial statements.

Industry Context

This filing is a routine amendment to correct a minor error in a financial report, which is not uncommon for publicly traded companies. It does not indicate any significant issues with the company's operations or financial health.

Comparison to Industry Standards

• The company's internal control assessment aligns with the COSO framework, a widely accepted standard for internal control evaluation.
• The company's disclosure controls and procedures are consistent with SEC requirements for public companies.
• The company's exemption from auditor attestation is a standard provision for emerging growth companies under the JOBS Act.

Stakeholder Impact

• The correction of the typographical error ensures that stakeholders have accurate information.
• The certification of effective controls provides stakeholders with confidence in the company's financial reporting.

Next Steps

• The company will continue to monitor the effectiveness of its internal control over financial reporting and disclosure controls and procedures.

Key Dates

Keywords

Form 20-F/A, Annual Report, Amendment, Disclosure Controls, Internal Control, Financial Reporting, Emerging Growth Company, Sarbanes-Oxley Act